Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Det lå blandt andet bag Novos beslutning om sidste år at investere omkring 80 milliarder kroner i tre nye fabrikker – heraf ...

Fabrikker og fedmemedicin udløser stigende klimaregning til NovoOnsdag morgen kunne Novo Nordisk fremvise et pænt årsregnskab ...

Medicinalselskabet Novo Nordisk overgik markedets forventninger med et overskud på 101 milliarder sidste år. Og analytikere ...

Novo Nordisk ser sig selv stå et godt sted over for højere amerikansk told, men selskabet er ikke immunt. Den danske ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...